[Skip to Navigation]
Sign In
Correction
March 9, 2022

Errors in Table and Abstract

JAMA Netw Open. 2022;5(3):e225056. doi:10.1001/jamanetworkopen.2022.5056

In the Original Investigation titled “Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom,”1 published January 10, 2022, there were data errors in the columns displaying results for the total cohort and incidence group under the header “Satukijchai et al” in Table 2 and an error in a 95% CI given in the Abstract for the association between transverse myelitis at onset and risk of relapse. This article has been corrected.1

References
1.
Satukijchai  C, Mariano  R, Messina  S,  et al.  Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody–associated disease in the United Kingdom.   JAMA Netw Open. 2022;5(1):e2142780. doi:10.1001/jamanetworkopen.2021.42780PubMedGoogle Scholar
×